Syon Capital LLC Sells 7,652 Shares of GSK plc (NYSE:GSK)

Syon Capital LLC trimmed its position in shares of GSK plc (NYSE:GSK - Free Report) by 23.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,662 shares of the pharmaceutical company's stock after selling 7,652 shares during the period. Syon Capital LLC's holdings in GSK were worth $868,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co increased its position in shares of GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new position in shares of GSK in the 4th quarter valued at $26,000. ST Germain D J Co. Inc. lifted its holdings in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 522 shares during the period. Sierra Ocean LLC acquired a new stake in shares of GSK during the 4th quarter valued at about $32,000. Finally, Parkside Financial Bank & Trust increased its stake in GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after acquiring an additional 818 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Price Performance

GSK stock opened at $37.03 on Thursday. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The firm has a market cap of $76.41 billion, a P/E ratio of 23.29, a P/E/G ratio of 1.12 and a beta of 0.56. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The business's fifty day moving average is $37.46 and its two-hundred day moving average is $36.06.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities research analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were paid a dividend of $0.3932 per share. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.25%. The ex-dividend date of this dividend was Friday, February 21st. GSK's dividend payout ratio is 100.63%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GSK shares. BNP Paribas started coverage on GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective on the stock. Morgan Stanley started coverage on GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday. Eight analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $40.58.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.